Cargando…
Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics
BACKGROUND: Several small studies have previously investigated associations between the cytochrome P450 2D6 (CYP2D6) metabolism and response to opioids. We used a large sample of patients to study associations between CYP2D6 phenotypes and estimated CYP2D6 enzymatic activity scores with pain control...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081062/ https://www.ncbi.nlm.nih.gov/pubmed/32214840 http://dx.doi.org/10.2147/PGPM.S239222 |
_version_ | 1783508107637293056 |
---|---|
author | Lopes, Guilherme S Bielinski, Suzette J Moyer, Ann M Black III, John Logan Jacobson, Debra J Jiang, Ruoxiang Larson, Nicholas B St Sauver, Jennifer L |
author_facet | Lopes, Guilherme S Bielinski, Suzette J Moyer, Ann M Black III, John Logan Jacobson, Debra J Jiang, Ruoxiang Larson, Nicholas B St Sauver, Jennifer L |
author_sort | Lopes, Guilherme S |
collection | PubMed |
description | BACKGROUND: Several small studies have previously investigated associations between the cytochrome P450 2D6 (CYP2D6) metabolism and response to opioids. We used a large sample of patients to study associations between CYP2D6 phenotypes and estimated CYP2D6 enzymatic activity scores with pain control and adverse reactions related to codeine and tramadol use. We conducted additional analyses to determine whether our results were consistent among men and women. METHODS: We used data from 2,877 participants in the RIGHT Protocol who were prescribed codeine and/or tramadol between 01/01/2005 and 12/31/2017 and who were not prescribed CYP2D6 inhibitors within 1 year prior to the opioid prescription. CYP2D6 phenotype categories were condensed into four groups: (1) Ultra-rapid and Rapid (n = 61), (2) Normal and Intermediate to Normal (n = 1,448), (3) Intermediate and Intermediate to Poor (n = 1,175), and (4) Poor metabolizer status (n = 193). Opioid-related outcomes included indications of poor pain control or adverse reactions related to medication use. We modeled the risk of each outcome using logistic regression, adjusting for age, sex, race, and ethnicity. RESULTS: The results revealed a trend from poor to ultra-rapid and rapid CYP2D6 phenotypes in which the risk of adverse reactions incrementally increased and the risk of poor pain control incrementally decreased. This trend reached statistical significance among female (but not male) participants. Among normal and intermediate to normal metabolizers, a larger proportion of women experienced adverse reactions relative to men. DISCUSSION: We replicated and extended the findings of previous research indicating associations between CYP2D6 phenotypes and response to opioids. In addition, the observed associations were stronger in women than in men. We recommend sex differences to be factored in future research investigating associations between pharmacogenomics and response to medications. |
format | Online Article Text |
id | pubmed-7081062 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-70810622020-03-25 Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics Lopes, Guilherme S Bielinski, Suzette J Moyer, Ann M Black III, John Logan Jacobson, Debra J Jiang, Ruoxiang Larson, Nicholas B St Sauver, Jennifer L Pharmgenomics Pers Med Original Research BACKGROUND: Several small studies have previously investigated associations between the cytochrome P450 2D6 (CYP2D6) metabolism and response to opioids. We used a large sample of patients to study associations between CYP2D6 phenotypes and estimated CYP2D6 enzymatic activity scores with pain control and adverse reactions related to codeine and tramadol use. We conducted additional analyses to determine whether our results were consistent among men and women. METHODS: We used data from 2,877 participants in the RIGHT Protocol who were prescribed codeine and/or tramadol between 01/01/2005 and 12/31/2017 and who were not prescribed CYP2D6 inhibitors within 1 year prior to the opioid prescription. CYP2D6 phenotype categories were condensed into four groups: (1) Ultra-rapid and Rapid (n = 61), (2) Normal and Intermediate to Normal (n = 1,448), (3) Intermediate and Intermediate to Poor (n = 1,175), and (4) Poor metabolizer status (n = 193). Opioid-related outcomes included indications of poor pain control or adverse reactions related to medication use. We modeled the risk of each outcome using logistic regression, adjusting for age, sex, race, and ethnicity. RESULTS: The results revealed a trend from poor to ultra-rapid and rapid CYP2D6 phenotypes in which the risk of adverse reactions incrementally increased and the risk of poor pain control incrementally decreased. This trend reached statistical significance among female (but not male) participants. Among normal and intermediate to normal metabolizers, a larger proportion of women experienced adverse reactions relative to men. DISCUSSION: We replicated and extended the findings of previous research indicating associations between CYP2D6 phenotypes and response to opioids. In addition, the observed associations were stronger in women than in men. We recommend sex differences to be factored in future research investigating associations between pharmacogenomics and response to medications. Dove 2020-03-13 /pmc/articles/PMC7081062/ /pubmed/32214840 http://dx.doi.org/10.2147/PGPM.S239222 Text en © 2020 Lopes et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Lopes, Guilherme S Bielinski, Suzette J Moyer, Ann M Black III, John Logan Jacobson, Debra J Jiang, Ruoxiang Larson, Nicholas B St Sauver, Jennifer L Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics |
title | Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics |
title_full | Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics |
title_fullStr | Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics |
title_full_unstemmed | Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics |
title_short | Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics |
title_sort | sex differences in associations between cyp2d6 phenotypes and response to opioid analgesics |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081062/ https://www.ncbi.nlm.nih.gov/pubmed/32214840 http://dx.doi.org/10.2147/PGPM.S239222 |
work_keys_str_mv | AT lopesguilhermes sexdifferencesinassociationsbetweencyp2d6phenotypesandresponsetoopioidanalgesics AT bielinskisuzettej sexdifferencesinassociationsbetweencyp2d6phenotypesandresponsetoopioidanalgesics AT moyerannm sexdifferencesinassociationsbetweencyp2d6phenotypesandresponsetoopioidanalgesics AT blackiiijohnlogan sexdifferencesinassociationsbetweencyp2d6phenotypesandresponsetoopioidanalgesics AT jacobsondebraj sexdifferencesinassociationsbetweencyp2d6phenotypesandresponsetoopioidanalgesics AT jiangruoxiang sexdifferencesinassociationsbetweencyp2d6phenotypesandresponsetoopioidanalgesics AT larsonnicholasb sexdifferencesinassociationsbetweencyp2d6phenotypesandresponsetoopioidanalgesics AT stsauverjenniferl sexdifferencesinassociationsbetweencyp2d6phenotypesandresponsetoopioidanalgesics |